Justin Ferayorni’s Tamarack Capital Management Reports Increase of Passive Stake In This Stock

However, despite this, investors like Tamarack consider that the company will turn around and therefore the stock will go up. Aside from Tamarack, another shareholder of Endologix among the funds that we track is James Flynn’s Deerfield Management, which owns around 4.48 million shares. Following a significant boost to its stake in October, Deerfield is the largest shareholder in Endologix, Inc. (NASDAQ:ELGX) among the funds that we track on record and its passive stake represents 6.7% of the company’s common stock. Another investor bullish on the company is Brian Ashford-Russell and Tim Woolley’s Polar Capital, which owns around 1.44 million shares as of the end of September. Overall, the majority of funds that we track have raised their exposure to Endologix during the third quarter, although their holdings represent small shares of their total equity portfolios.

Insiders have also been trading shares of Endologix, Inc. (NASDAQ:ELGX) pretty actively over the last several months. For example, Charles Love, the Vice-President for Clinical Affaris, has bought 2,000 shares in November and disposed of 10,000 shares in December. Following these transactions, the insider holds some 35,000 shares of the company.

Analysts are also optimistic on Endologix, Inc. (NASDAQ:ELGX)’s prospects, since the company has a consensus ‘Buy’ rating and boasts a strong average target price of around $16.70. Earlier this year, BTIG Research downgraded the stock to ‘Neutral’ from ‘Buy’ and at the end of 2014, Piper Jaffray raised their price target to $21.00 from $18.00, reiterating ‘Overweight’ rating.

Disclosure: none